Skip to main content
Challenges in Gout Diagnosis

Dr. Angelo Gaffo in Birmingham, AL discusses the challenges in diagnosing gout. Presented

Dr. John Cush RheumNow

2 weeks 3 days ago
Challenges in Gout Diagnosis Dr. Angelo Gaffo in Birmingham, AL discusses the challenges in diagnosing gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026. https://t.co/LmTj7cvBGT https://t.co/VRVCrAo2TT
QD CLINIC: Senior Year Gout

Daric Mueller, PA-C, discusses a case of difficult-to-treat gout in an individual first di

Dr. John Cush RheumNow

2 weeks 3 days ago
QD CLINIC: Senior Year Gout Daric Mueller, PA-C, discusses a case of difficult-to-treat gout in an individual first diagnosed at age 18 who is now in his early 30s. This QD Clinic is presented as part of RheumNow's "Gout: More than Flares" campaign. https://t.co/9GNk8ZqwyS https://t.co/hAFz6zPcay
In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.
Weight loss helps gout, but extreme weight loss (bariatric surgery, ketogenic diets) may trigger gouty attacks. (Not see

Dr. John Cush RheumNow

2 weeks 3 days ago
Weight loss helps gout, but extreme weight loss (bariatric surgery, ketogenic diets) may trigger gouty attacks. (Not seen with GLP-1 agonist weight loss) For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/LGEENexSZ6
Subanalysis of SURMOUNT-1 Obesity trial l (2539 pts w/ BMI ≥ 30; tirzepatide vs PBO) showed 21% wt loss by wk 72 w/ TI

Dr. John Cush RheumNow

2 weeks 3 days ago
Subanalysis of SURMOUNT-1 Obesity trial l (2539 pts w/ BMI ≥ 30; tirzepatide vs PBO) showed 21% wt loss by wk 72 w/ TIRZ. Serum uric acid (SUA) decr by -0.69, -0.92, & -0.95 mg/dL on TIRZ (5, 10, & 15 mg qd). Wt loss explained 73% of SUA reduction. https://t.co/V0stEDC4lF https://t.co/t8qNNCrrGM
NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan

The New England Journal of Medicine (NEJM) retracted the

Dr. John Cush RheumNow

2 weeks 3 days ago
NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. https://t.co/GOVyk5poNq
DMARD Efficacy in RA-ILD

A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for

Dr. John Cush RheumNow

2 weeks 3 days ago
DMARD Efficacy in RA-ILD A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional,
CAR-T therapy in autoimmune disease is moving fast - but is it ready to move beyond specialized referral centers? This EULAR 2026 recap covers the mechanistic data, relapse biology, and access innovations shaping that answer.
The Power of Self-Management with Chronic Low Back Pain

Almost everyone will deal with back pain at some point in their

Dr. John Cush RheumNow

2 weeks 4 days ago
The Power of Self-Management with Chronic Low Back Pain Almost everyone will deal with back pain at some point in their lives. Most recover quickly — but for about 20% of people, acute pain becomes a chronic condition that interferes with daily life and keeps them out of the https://t.co/urZPsVwCV8
Uric Acid: Is Lower Better?

There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully red

Dr. John Cush RheumNow

2 weeks 4 days ago
Uric Acid: Is Lower Better? There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs? https://t.co/yVZOuMhZmr https://t.co/Ldc1pBQThH
< 40% of gout patients are on ULT; <40% of ULT-treated gout patients achieve T2T (SUA < 6.0 mg/dl).
For more go

Dr. John Cush RheumNow

2 weeks 4 days ago
< 40% of gout patients are on ULT; <40% of ULT-treated gout patients achieve T2T (SUA < 6.0 mg/dl). For more gout content, follow our Gout: More than Flares campaign at https://t.co/j3iLMZz4HM, https://t.co/zFTozS62me
TNR: Gout Journal Club
How should imaging guide the diagnosis and management of gout?

Hear from Dr. Nicola Dalbeth, Dr. John Fitzgerald, and D

Dr. John Cush RheumNow

2 weeks 4 days ago
How should imaging guide the diagnosis and management of gout? Hear from Dr. Nicola Dalbeth, Dr. John Fitzgerald, and Dr. Sarah Tedeschi, moderated by Dr. Jack Cush, as they discuss ultrasound, DECT, crystal identification, and more. 📅 Reserve your seat today. Link: https://t.co/GySPzyVc1b
Gout is more than an episodic arthritis, it's a systemic inflammatory disease.

Watch Dr. Robert Terkeltaub discuss 3 Ne

Dr. John Cush RheumNow

2 weeks 4 days ago
Gout is more than an episodic arthritis, it's a systemic inflammatory disease. Watch Dr. Robert Terkeltaub discuss 3 New Things it Pays to Know About Gout Pathobiology, including emerging insights that are shaping how we understand and manage gout. Watch now on RheumNow: https://t.co/nri3WDz7kS
×